Overview

Biperiden Trial for Epilepsy Prevention

Status:
Not yet recruiting
Trial end date:
2026-12-20
Target enrollment:
Participant gender:
Summary
One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital Sirio-Libanes
Collaborators:
Ministry of Health, Brazil
PROADI-SUS
Treatments:
Biperiden